Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...

AbbVie partners with Simcere Zaiming in up to $1.1B deal to develop SIM0500 for multiple myeloma; drug currently in Phase 1 ...